Document and Entity Information (USD $) In Millions, except Share data, unless otherwise specified	6 Months Ended
	Jun. 30, 2010	Jul. 26, 2010	Jun. 30, 2009
Document and Entity Information [Abstract]
Entity Registrant Name	INTEGRA LIFESCIENCES HOLDINGS CORP
Entity Central Index Key	0000917520
Document Type	10-Q
Document Period End Date	Jun. 30, 2010
Amendment Flag	false
Document Fiscal Year Focus	2010
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 541.3
Entity Common Stock, Shares Outstanding		29,077,780

Condensed Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2010	Jun. 30, 2009	Jun. 30, 2010	Jun. 30, 2009
Condensed Consolidated Statements of Operations [Abstract]
Total Revenue	$ 178,595	$ 165,725	$ 351,293	$ 326,675
Costs and Expenses:
Cost of product revenues	64,464	59,805	127,688	117,953
Research and development	11,761	10,302	23,062	20,945
Selling, general and administrative	74,216	68,252	146,727	134,703
Intangible asset amortization	3,575	3,461	6,594	6,917
Total costs and expenses	154,016	141,820	304,071	280,518
Operating income	24,579	23,905	47,222	46,157
Interest income	52	134	113	381
Interest expense	(4,300)	(6,174)	(8,841)	(12,858)
Other income (expense), net	763	(481)	1,909	(1,349)
Income before income taxes	21,094	17,384	40,403	32,331
Income tax expense	5,937	6,159	10,024	11,539
Net income	$ 15,157	$ 11,225	$ 30,379	$ 20,792
Basic net income per common share	$ 0.51	$ 0.38	$ 1.02	$ 0.71
Diluted net income per common share	$ 0.5	$ 0.38	$ 1	$ 0.71
Weighted average common shares outstanding (See Note 10):
Basic	29,855	29,004	29,672	28,974
Diluted	30,399	29,202	30,282	29,228

Condensed Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	6 Months Ended	12 Months Ended
	Jun. 30, 2010	Dec. 31, 2009
Current Assets:
Cash and cash equivalents	$ 93,618	$ 71,891
Trade accounts receivable, net of allowances of $9,578 and $11,216	97,779	103,228
Inventories, net	143,253	140,240
Deferred tax assets	29,526	29,972
Prepaid expenses and other current assets	23,455	20,032
Total current assets	387,631	365,363
Property, plant and equipment, net	84,644	83,526
Intangible assets, net	201,174	211,117
Goodwill	252,143	261,941
Deferred tax assets	14,228	15,841
Other assets	1,975	2,314
Total assets	941,795	940,102
Current Liabilities:
Convertible securities	0	76,760
Accounts payable, trade	32,906	24,598
Deferred revenue	4,001	4,077
Accrued compensation	21,522	23,227
Accrued expenses and other current liabilities	27,210	28,068
Total current liabilities	85,639	156,730
Long-term borrowings under senior credit facility	220,000	160,000
Long-term convertible securities	151,900	148,754
Deferred tax liabilities	7,655	9,319
Other liabilities	16,225	20,414
Total liabilities	481,419	495,217
Commitments and contingencies
Stockholders' Equity:
Preferred Stock; no par value; 15,000 authorized shares; none outstanding	0	0
Common stock; $.01 par value; 60,000 authorized shares; 35,332 and 34,958 issued at June 30, 2010 and December 31, 2009, respectively	353	350
Additional paid-in capital	533,863	520,849
Treasury stock, at cost; 6,354 shares at June 30, 2010 and December 31, 2009	(252,380)	(252,380)
Accumulated other comprehensive (loss) income:
Foreign currency translation adjustment	(18,187)	9,746
Pension liability adjustment, net of tax	(821)	(860)
Unrealized gain on derivatives, net of tax	8	19
Retained earnings	197,540	167,161
Total stockholders' equity	460,376	444,885
Total liabilities and stockholders' equity	$ 941,795	$ 940,102

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2010	Dec. 31, 2009
Current Assets:
Trade accounts receivable, allowances	$ 9,578	$ 11,216
Stockholders' Equity:
Preferred Stock, par value	$ 0	$ 0
Preferred Stock, authorized shares	15,000	15,000
Preferred Stock, outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	60,000	60,000
Common stock, shares issued	35,332	34,958
Treasury stock, shares	6,354	6,354

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2010	Jun. 30, 2009
OPERATING ACTIVITIES:
Net income	$ 30,379	$ 20,792
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	18,954	17,143
Deferred income tax benefit	(375)	(1,850)
Amortization of bond issuance costs	674	1,434
Non-cash interest expense	3,941	5,527
Payment of accreted interest	(6,599)	(2,722)
Gain on bond repurchases		(1,124)
Loss on disposal of property and equipment	447
Share-based compensation	7,520	7,731
Excess tax benefits from stock-based compensation arrangements	(3,474)	(7)
Changes in assets and liabilities, net of business acquisitions:
Accounts receivable	2,687	9,906
Inventories	(7,754)	6,237
Prepaid expenses and other current assets	(3,877)	8,487
Other non-current assets	202	5,424
Accounts payable, accrued expenses and other current liabilities	6,041	(8,931)
Deferred revenue	(715)	(344)
Other non-current liabilities	(556)	122
Net cash provided by operating activities	47,495	67,825
INVESTING ACTIVITIES:
Cash used in business acquisition, net of cash acquired	(2,421)	(4,141)
Purchases of property and equipment	(11,691)	(8,269)
Net cash used in investing activities	(14,112)	(12,410)
FINANCING ACTIVITIES:
Borrowings under senior credit facility	75,000
Repayments under senior credit facility	(15,000)	(60,000)
Repurchase of liability component of convertible notes	(71,351)	(44,819)
Proceeds from exercised stock options	4,633	592
Excess tax benefits from stock-based compensation arrangements	3,474	7
Net cash used in financing activities	(3,244)	(104,220)
Effect of exchange rate changes on cash and cash equivalents	(8,412)	3,976
Net change in cash and cash equivalents	21,727	(44,829)
Cash and cash equivalents at beginning of period	71,891	183,546
Cash and cash equivalents at end of period	93,618	138,717
Supplemental disclosure of non-cash activity:
Stock options, net-share exercised	282
Number of shares tendered and retired under stock option plan	74
Shares tendered and retired under stock option plan, value	$ 3,100

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2010
Basis of Presentation [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION General The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise. In the opinion of management, the June 30, 2010 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2009 included in the Company’s Annual Report on Form 10-K. The December 31, 2009 condensed consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. Operating results for the six-month period ended June 30, 2010 are not necessarily indicative of the results to be expected for the entire year. The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, valuation of intangible assets and in-process research and development, pension assets and liabilities, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. Certain amounts from the prior year’s financial statements have been reclassified in order to conform to the current year’s presentation.

- Definition

Description containing the entire organization, consolidation and basis of presentation of financial statements disclosure. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References+ Details

Business and Asset Acquisitions

6 Months Ended

Jun. 30, 2010

Business and Asset Acquisitions [Abstract]

BUSINESS AND ASSET ACQUISITIONS

2. BUSINESS AND ASSET ACQUISITIONS

Welch Allyn, Inc.

In May 2010, the Company acquired certain assets and liabilities of the surgical headlight business of Welch Allyn, Inc. (“Welch”) for approximately $2.4 million in cash and $0.2 million of working capital adjustments. The Company has determined that these assets and liabilities met the definition of a business under the authoritative guidance. The Company believes that the assets acquired will further its goal of expanding its reach into the surgical headlight market. The Company also entered into a development agreement with Welch that expires on February 15, 2011 unless the product is commercially available prior to that date.

The final purchase price has been allocated as follows (in thousands):


Accounts receivable	$	518
Inventory		138
Property, plant and equipment		280
Intangible assets			Wtd. Avg. Life
Customer relationships		490	15 years
Technology		263	6 years
In-Process research and development		312	Indefinite
Goodwill		601


Total net assets acquired	$	2,602

Athrodax Healthcare International Ltd.

In December 2009, the Company acquired certain assets as well as the distribution rights for its Newdeal^{^®} product lines in the United Kingdom from Athrodax Healthcare International Ltd. (“Athrodax”), for approximately $3.3 million (2.0 million British Pounds) in cash, subject to certain adjustments for working capital items. For the previous ten years Athrodax had been the Company’s distributor of extremity reconstruction products in the United Kingdom. The acquisition provides the Company with the opportunity to distribute orthopedic products directly to its United Kingdom customers, and included an experienced sales team in the foot and ankle surgery market which had successfully developed its brand in the United Kingdom.

Innovative Spinal Technologies, Inc.

In August 2009, the Company acquired certain assets and liabilities of Innovative Spinal Technologies, Inc. (“IST”) for approximately $9.3 million in cash and $0.2 million in acquisition expenses. IST’s focus was on spinal implant products related to minimally invasive surgery and motion preservation techniques. We acquired three product lines, various product development assets for posterior dynamic stabilization, various patents and trademarks and inventory, and we also assumed certain of IST’s patent license agreements and related obligations. The assets and liabilities acquired did not meet the definition of a business under the authoritative guidance for business combinations. Accordingly, the assets and liabilities have been recognized at fair value with no related goodwill.

Theken

In August 2008 the Company acquired Theken Spine, LLC, Theken Disc, LLC and Therics, LLC (collectively, “Integra Spine”) for $75.0 million in cash, acquisition expenses of $2.4 million, working capital adjustments of $3.9 million, and up to an additional $125.0 million in future payments based on the revenue performance of the business in each of the two years after closing. We paid approximately $52.0 million of the potential revenue performance obligation in November 2009. Integra Spine, based in Akron, Ohio, designs, develops and manufactures spinal fixation products.

Inventories

6 Months Ended

Jun. 30, 2010

Inventories [Abstract]

INVENTORIES

3. INVENTORIES

Inventories, net consisted of the following:


	June 30,			December 31,
	2010			2009
	(in thousands)
Finished goods	$	109,898		$	109,077
Work-in process		30,174			28,757
Raw materials		32,379			30,131
Less: reserves		(29,198	)		(27,725	)


	$	143,253		$	140,240

Goodwill and Other Intangible Assets

6 Months Ended

Jun. 30, 2010

Goodwill and Other Intangible Assets [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

4. GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the carrying amount of goodwill for the six months ended June 30, 2010 were as follows (in thousands):


Goodwill	$	261,941
Accumulated impairment losses		—


Goodwill at December 31, 2009		261,941
Foreign currency translation		(10,399	)
Welch Allyn acquisition		601


Goodwill at June 30, 2010	$	252,143

The Company’s assessment of the recoverability of goodwill is based upon a comparison of the carrying value of goodwill with its estimated fair value, determined using a discounted cash flow methodology. The Company performs this assessment annually during the second quarter and no impairment resulted after completing this assessment during the second quarter of 2010.

During the second quarter of 2010, the Company recorded a $0.8 million impairment charge related to several brand names. The impairment charge relates to management’s decision with respect to the Company’s re-branding strategy for several legacy brand names. The Company has recorded the charge as a component of amortization expense.

The components of the Company’s identifiable intangible assets were as follows (in thousands):


	Weighted	June 30, 2010							December 31, 2009
	Average			Accumulated							Accumulated
	Life	Cost		Amortization			Net		Cost		Amortization			Net

Completed technology	12 years	$	68,771	$	(24,799	)	$	43,972	$	69,632	$	(22,526	)	$	47,106
Customer relationships	12 years		97,025		(40,573	)		56,452		97,922		(36,724	)		61,198
Trademarks/brand names	35 years		33,023		(7,781	)		25,242		35,741		(8,692	)		27,049
Trademarks/brand names	Indefinite		49,384		—			49,384		49,384		—			49,384
Supplier relationships	30 years		29,300		(4,037	)		25,263		29,300		(3,647	)		25,653
All other*	15 years*		8,364		(7,503	)		861		8,197		(7,470	)		727


		$	285,867	$	(84,693	)	$	201,174	$	290,176	$	(79,059	)	$	211,117


*		All other includes $0.3 million of in-process research and development which is indefinite lived.

Annual amortization expense is expected to approximate $17.7 million in 2010, $16.6 million in 2011, $16.4 million in 2012, $13.7 million in 2013 and $12.7 million in 2014. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition using an income or cost approach.

- Definition

Discloses the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain or loss on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. This element may be used as a single block of text to include the entire intangible asset disclosure including data and tables.

+ References+ Details

Debt	6 Months Ended
Debt	Jun. 30, 2010
Debt [Abstract]
DEBT	5. DEBT 2010 and 2012 Senior Convertible Notes On June 11, 2007, the Company issued $165.0 million aggregate principal amount of its 2010 Notes and $165.0 million aggregate principal amount of its 2012 Notes (the 2010 Notes and the 2012 Notes, collectively the “Notes”). The 2010 Notes and the 2012 Notes bear interest at a rate of 2.75% per annum and 2.375% per annum, respectively, in each case payable semi-annually in arrears on December 1 and June 1 of each year. In 2009, the Company repurchased a total principal amount of $87.1 million of the 2010 Notes and recognized a gain of $0.5 million. Total cash paid for these repurchases was $83.3 million of which $78.0 million related to repayment of the liability component of the Notes. For all of these transactions, the bond hedge contracts were terminated on a pro-rata basis and the number of options was adjusted to reflect the number of convertible securities outstanding that together have a total principal amount of $77.9 million. Also, in connection with the repurchases, in separate transactions, we amended the warrant transactions to reduce the number of warrants outstanding to reflect such number of convertible securities outstanding. The Company repaid the remaining $77.9 million principal amount in June 2010 in accordance with the agreement, of which $71.4 million was related to the liability component and $6.6 million was for accreted interest. The principal amount outstanding under the 2012 Notes at June 30, 2010 was $165.0 million. The fair value of the 2012 Notes at June 30, 2010 was approximately $161.6 million. The 2012 Notes are senior, unsecured obligations of the Company, and are convertible into cash and, if applicable, shares of its common stock based on an initial conversion rate, subject to adjustment, of 15.3935 shares per $1,000 principal amount of notes (which represents an initial conversion price of approximately $64.96 per share). The Company will satisfy any conversion of the 2012 Notes with cash up to the principal amount pursuant to the net share settlement mechanism set forth in the indenture and, with respect to any excess conversion value, with shares of the Company’s common stock. The 2012 Notes are convertible only in the following circumstances: (1) if the closing sale price of the Company’s common stock exceeds 130% of the conversion price during a period as defined in the indenture; (2) if the average trading price per $1,000 principal amount of the Notes is less than or equal to 97% of the average conversion value of the Notes during a period as defined in the indenture; (3) at any time on or after December 15, 2011; or (4) if specified corporate transactions occur. However, none of these conditions existed at June 30, 2010 and, as a result, the 2012 Notes are classified as long term. The issue price of the 2012 Notes was equal to their face amount, which is also the amount holders are entitled to receive at maturity if the 2012 Notes are not converted. Holders of the 2012 Notes, who convert their notes in connection with a qualifying fundamental change, as defined in the indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, following the occurrence of a fundamental change, holders may require that the Company repurchase some or all of the 2012 Notes for cash at a repurchase price equal to 100% of the principal amount of the notes being repurchased, plus accrued and unpaid interest, if any. The 2012 Notes, under the terms of the private placement agreement, are guaranteed fully by Integra LifeSciences Corporation, a subsidiary of the Company. The 2012 Notes will be the Company’s direct senior unsecured obligations and will rank equal in right of payment to all of the Company’s existing and future unsecured and unsubordinated indebtedness. In connection with the original issuance of the Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the Notes (the “hedge participants”), in connection with each series of Notes. The cost of the call transactions to the Company was approximately $46.8 million. The Company received approximately $21.7 million of proceeds from the warrant transactions. The call transactions involve the Company’s purchasing call options from the hedge participants, and the warrant transactions involve the Company’s selling call options to the hedge participants with a higher strike price than the purchased call options. The calls related to the 2010 Notes expired with the maturity of those notes and the warrants related to the 2010 Notes expire at various times through January 2011. The initial strike price of the remaining call transactions is approximately $64.96 for the 2012 Notes, subject to anti-dilution adjustments substantially similar to those in the 2012 Notes. The initial strike price of the warrant transactions is (x) for the 2010 Notes, approximately $77.96 per share of Common Stock and (y) for the 2012 Notes, approximately $90.95, in each case subject to customary anti-dilution adjustments. Senior Secured Revolving Credit Facility As of June 30, 2010, the Company had $220.0 million of outstanding borrowings under this credit facility at a weighted average interest rate of 1.13%. The fair value of the outstanding borrowings on this credit facility at June 30, 2010 was approximately $211.9 million. During the six months ended June 30, 2010, the Company borrowed $75.0 million in connection with the maturity of its 2010 Notes and also repaid $15.0 million of its outstanding borrowings. The Company considers all such outstanding amounts to be long-term in nature based on its current intent and ability to repay the borrowing outside of the next twelve-month period. This credit facility expires in December 2011.

Derivative Instruments	6 Months Ended
Derivative Instruments	Jun. 30, 2010
Derivative Instruments [Abstract]
DERIVATIVE INSTRUMENTS	6. DERIVATIVE INSTRUMENTS The Company utilizes a foreign currency forward exchange contract to hedge an anticipated intercompany transaction in euros and designates this derivative instrument as a cash-flow hedge. Our forward exchange contract has a notional amount of 8.2 million euros ($10.0 million at June 30, 2010), and is short term in nature with a term of less than twelve months. This forward exchange contract matches the currency, timing and notional amount of underlying forecasted transactions. Therefore, no ineffectiveness resulted or was recorded through the condensed consolidated statement of operations. As of June 30, 2010, this forward exchange contract has an aggregate U.S. dollar equivalent fair value amounting to net losses of $2.2 million included in other current liabilities. The net gains or losses from this cash flow hedge reported in accumulated other comprehensive income is reclassified to earnings and recorded in other income in our consolidated statement of operations as the foreign currency rates fluctuate over the term of the instrument. At June 30, 2010, the amount of net unrealized gains in other comprehensive income which will be recognized as an increase to other income in the remainder of 2010 was not significant. The Company considers the credit risk related to the forward exchange contract to be low because the instrument was entered into with a financial institution with a high credit rating.

Stock-Based Compensation	6 Months Ended
Stock-Based Compensation	Jun. 30, 2010
Stock-Based Compensation [Abstract]
STOCK-BASED COMPENSATION	7. STOCK-BASED COMPENSATION As of June 30, 2010, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under six plans, the 1996 Incentive Stock Option and Non-Qualified Stock Option Plan (the “1996 Plan”), the 1998 Stock Option Plan (the “1998 Plan”), the 1999 Stock Option Plan (the “1999 Plan”), the 2000 Equity Incentive Plan (the “2000 Plan”), the 2001 Equity Incentive Plan (the “2001 Plan”), and the 2003 Equity Incentive Plan (the “2003 Plan,” and collectively, the “Plans”). No new awards may be granted under the 1996 Plan, the 1998 Plan, the 1999 Plan and the 2000 Plan. Stock options issued under the Plans become exercisable over specified periods, generally within four years from the date of grant for officers, directors and employees, and generally expire six years from the grant date for employees and from six to ten years for directors and certain executive officers. The transfer and non-forfeiture provisions of restricted stock issued under the Plans lapse over specified periods, generally three years after the date of grant. Stock Options The Company granted approximately 59,000 and 62,500 stock options during the six months ended June 30, 2010 and June 30, 2009, respectively. As of June 30, 2010, there were approximately $3.8 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately 1.9 years. The Company received net proceeds of $4.6 million and $0.6 million from stock option exercises for the six months ended June 30, 2010 and 2009, respectively. Awards of Restricted Stock, Performance Stock and Contract Stock Performance stock awards have performance features associated with them. Performance stock, restricted stock and contract stock awards generally have requisite service periods of three years. The fair value of these awards is being expensed on a straight-line basis over the vesting period or requisite service period, whichever is shorter. As of June 30, 2010, there was approximately $13.4 million of total unrecognized compensation costs related to unvested awards. These costs are expected to be recognized over a weighted-average period of approximately 1.8 years. The Company has no formal policy related to the repurchase of shares for the purpose of satisfying stock-based compensation obligations. The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees of the Company with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.

Retirement Benefit Plans

6 Months Ended

Jun. 30, 2010

Retirement Benefit Plans [Abstract]

RETIREMENT BENEFIT PLANS

8. RETIREMENT BENEFIT PLANS

The Company maintains defined benefit pension plans that cover employees in its manufacturing plants located in Andover, United Kingdom (the “UK Plan”) and Tuttlingen, Germany (the “Germany Plan”). The Company closed the Tuttlingen, Germany plant, to which the Germany Plan pertained, in December 2005. However, the Company did not terminate the Germany Plan and the Company remains obligated for the accrued pension benefits related to this plan. The plans cover certain current and former employees. Net periodic benefit costs for the Company’s defined benefit pension plans included the following amounts (in thousands):


	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2009			2010			2009
Service cost	$	26		$	30		$	53		$	57
Interest cost		155			151			313			285
Expected return on plan assets		(119	)		(103	)		(244	)		(199	)
Recognized net actuarial loss		36			115			74			222


Net period benefit cost	$	98		$	193		$	196		$	365

The Company made $0.5 million and $0.4 million of contributions to its defined benefit pension plans during the six months ended June 30, 2010 and 2009, respectively.

- Definition

Description containing the entire pension and other postretirement benefits disclosure as a single block of text.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 158

-Paragraph 7, 21, 22

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5, 6, 7, 8

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 8

-Subparagraph m

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 106

-Paragraph 518

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 87

-Paragraph 264

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5

-Subparagraph b

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5

-Subparagraph a

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5

-Subparagraph h

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5

-Subparagraph q

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS106-2

-Paragraph 20, 21, 22

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 03-2

-Paragraph 8

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 30

-Paragraph 26

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Implementation Guide (Q and A)

-Number FAS88

-Paragraph 63

+ Details

Comprehensive (Loss) Income

6 Months Ended

Jun. 30, 2010

Comprehensive (Loss) Income [Abstract]

COMPREHENSIVE (LOSS) INCOME

9. COMPREHENSIVE (LOSS) INCOME

Comprehensive (loss) income was as follows (in thousands):


	Three Months Ended June 30,					Six Months Ended June 30,
	2010			2009		2010			2009
Net Income	$	15,157		$	11,225	$	30,379		$	20,792
Foreign currency translation adjustment		(16,704	)		13,691		(27,933	)		5,726
Change in unrealized gain on derivatives, net of tax		(5	)		—		(11	)		—


Comprehensive (loss) income	$	(1,552	)	$	24,916	$	2,435		$	26,518

- Definition

This label may include the following: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains and losses on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains and losses on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealized holding gains and losses on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7) the net gain or loss and net prior service cost or credit for pension plans and other postretirement benefit plans.

+ References+ Details

Net Income Per Share

6 Months Ended

Jun. 30, 2010

Net Income Per Share [Abstract]

NET INCOME PER SHARE

10. NET INCOME PER SHARE

In January 2009 the Company adopted the authoritative guidance related to determining whether instruments issued in share-based payment transactions are participating securities. Certain of the Company’s unvested restricted share units contain rights to receive nonforfeitable dividends, and thus, are participating securities requiring the two-class method of computing earnings per share. Because these securities had an insignificant impact on the calculation of earnings per share (impacts the rounding by $0.01 or less per share) the Company does not present the full calculation below.

Basic and diluted net income per share was as follows (in thousands, except per share amounts):


	Three Months Ended June 30,				Six Months Ended June 30,
	2010		2009		2010		2009
Basic net income per share:
Net income	$	15,157	$	11,225	$	30,379	$	20,792
Weighted average common shares outstanding		29,855		29,004		29,672		28,974
Basic net income per common share	$	0.51	$	0.38	$	1.02	$	0.71

Diluted net income per share:
Net income	$	15,157	$	11,225	$	30,379	$	20,792
Weighted average common shares outstanding — Basic		29,855		29,004		29,672		28,974
Effect of dilutive securities:
Stock options and restricted stock		544		198		610		254

Weighted average common shares for diluted earnings per share		30,399		29,202		30,282		29,228

Diluted net income per share	$	0.50	$	0.38	$	1.00	$	0.71

At June 30, 2010 and 2009 the Company had 1.9 million and 2.6 million of outstanding stock options, respectively. The Company also has warrants outstanding relating to its 2010 Notes and 2012 Notes. Stock options, restricted stock and warrants are included in the diluted earnings per share calculation using the treasury stock method, unless the effect of including the stock options would be anti-dilutive. For the three months ended June 30, 2010 and 2009, 0.7 million and 2.3 million anti-dilutive stock options, respectively, were excluded from the diluted earnings per share calculation. As the strike price of the warrants exceeded the Company’s average stock price for the period, the warrants are anti-dilutive and the entire number of warrants were also excluded from the diluted earnings per share calculation.

Segment and Geographic Information

6 Months Ended

Jun. 30, 2010

Segment and Geographic Information [Abstract]

SEGMENT AND GEOGRAPHIC INFORMATION

11. SEGMENT AND GEOGRAPHIC INFORMATION

The Company’s management, including the chief operating decision maker, reviews financial results and manages the business on an aggregate basis. Therefore, financial results are reported in a single operating segment, the development, manufacture and marketing of medical devices for use in cranial and spinal procedures, peripheral nerve repair, small bone and joint injuries, and the repair and reconstruction of soft tissue.

Revenue consisted of the following:


	Three Months Ended June 30,				Six Months Ended June 30,
	2010		2009		2010		2009
Integra Orthopedics	$	72,819	$	65,164	$	143,006	$	129,530
Integra NeuroSciences		66,306		61,448		131,080		121,179
Integra Medical Instruments		39,470		39,113		77,207		75,966


Total revenues	$	178,595	$	165,725	$	351,293	$	326,675

Total revenues by major geographic area are summarized below (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2010		2009		2010		2009
United States	$	138,760	$	127,086	$	268,123	$	249,671
Europe		20,076		23,035		44,228		46,429
Asia Pacific		9,174		7,935		18,411		15,129
Other Foreign		10,585		7,669		20,531		15,446


Total revenues	$	178,595	$	165,725	$	351,293	$	326,675

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2010
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	12. COMMITMENTS AND CONTINGENCIES In consideration for certain technology, manufacturing, distribution and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on the sales of products that are commercialized relative to the granted rights and licenses. Royalty payments made by the Company under these agreements were not significant for any of the periods presented. Various lawsuits, claims and proceedings are pending or have been settled by the Company. The only significant item is described below. In January 2010, the Company received a notice from the seller’s representative of the former Theken companies of a disagreement in the calculation of “trade sales” used in calculating a revenue performance payment that the Company made in November 2009. The notice alleges that the Company owes an additional $6.7 million. We are currently discussing this matter with the seller’s representative in an attempt to resolve the dispute in accordance with the provisions contained in the asset purchase agreement governing the transaction. In addition to this matter, the Company is subject to various claims, lawsuits and proceedings in the ordinary course of its business, including claims by current or former employees, distributors and competitors and with respect to its products. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material adverse effect on the Company’s financial condition. However, it is possible that its results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies. The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds, and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.

Income Taxes

6 Months Ended

Jun. 30, 2010

Income Taxes [Abstract]

INCOME TAXES

13. Income Taxes

The following table provides a summary of our effective tax rate:


							Percentage Point
	Three Months Ended June 30,						Increase
	2010			2009			(Decrease)

Reported tax rate		28.1	%		35.4	%		(7.3	%)


							Percentage Point
	Six Months Ended June 30,						Increase
	2010			2009			(Decrease)

Reported tax rate		24.8	%		35.7	%		(10.9	%)

The decrease in the Company’s effective tax rates for the second quarter and first half of 2010, as compared the same periods in 2009, relates primarily to an increase in the expected proportion of the Company’s taxable income for the full year that will come from foreign jurisdictions with lower tax rates. Additionally, during the first quarter of 2010 the Company reversed $2.3 million of reserves for uncertain tax positions due to matters that are considered effectively settled and the expiration of the statute of limitations for certain matters.

Leases	6 Months Ended
Leases	Jun. 30, 2010
Leases [Abstract]
LEASES	14. LEASES On March 1, 2010, the Company exercised an option to extend a lease agreement for production equipment dated June 2000 with Medicus Corporation. Under the option, the term of the original lease agreement was extended through March 31, 2012. The initial June 2000 agreement was subsequently amended on June 29, 2010 to extend the term of the lease to March 31, 2022, with an option to renew through March 31, 2032. The sole stockholder of Medicus Corporation is Provco Ventures I, LP, of which the Company’s chairman serves as partner and president.